#EULAR2024 POS0375 Negative trial need to be reported too. Phase 2 RCT of S95011, an IL7-R antibody in moderate to sever
Tweet Content
#EULAR2024 POS0375 Negative trial need to be reported too. Phase 2 RCT of S95011, an IL7-R antibody in moderate to severe systemic #Sjogren failed to meet primary endpoint (ESSDAI) or other secondary (ESSPRI, biomarkers). This inhibition unlikely to impact on SjD @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off